Piper Jaffray Starts Sutro Biopharma (STRO) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Piper Jaffray Starts Sutro Biopharma (STRO) at Overweight
October 22, 2018 6:18 AM EDT
Wedbush analyst David Nierengarten initiates coverage on Sutro Biopharma (NASDAQ: STRO) with a Outperform rating and a price target of $20.00.
For an analyst ratings summary and ratings history on Sutro Biopharma click here. For more ratings news on Sutro Biopharma click here.
Shares of Sutro Biopharma closed at $14.53 yesterday.
...
More
October 22, 2018 5:40 AM EDT
Cowen analyst Boris Peaker initiates coverage on Sutro Biopharma (NASDAQ: STRO) with a Outperform rating.
The analyst comments "Sutro is an early-clinical stage biopharma company that uses its XpressCF platform to generate optimized biologics. This platform generates a homologous pool of ADC... More
October 22, 2018 4:04 AM EDT
JMP Securities analyst Konstantinos Aprilakis initiates coverage on Sutro Biopharma (NASDAQ: STRO) with a Market Outperform rating and a price target of $28.00.
The analyst comments "Sutro is a clinical-stage biopharmaceutical company evolving novel methods to discover and develop protein-based therapies, with the... More
